Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by GC Cell Corporation, now recruiting.
Overview
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer is a phase 3 interventional study registered as NCT04969731 by GC Cell Corporation, with 408 participants planned, started 2021-09-07 and due to reach its primary completion in 2026-12. Interventions recorded: Immuncell-LC, Gemcitabine. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Setting
An Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Immuncell-LC Therapy Combined With Gemcitabine Versus Adjuvant Gemcitabine Single Therapy After Resection in Patients With Pancreatic Ductal Adenocarcinoma
Phase
Phase 3
Sponsor
GC Cell Corporation
Registry
Enrolled
408
Similar pages
not linked directly; found by shared links- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
- TrialANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- TrialSafety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
- TrialA Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer